Improving the Efficiency of Vγ9Vδ2 T-Cell Immunotherapy in Cancer

Timm Hoeres*, Manfred Smetak, Dominik Pretscher and Martin Wilhelm

Department of Hematology and Medical Oncology, Paracelsus Medical University, Nuremberg, Germany

Increasing immunological knowledge and advances in techniques lay the ground for more efficient and broader application of immunotherapies. gamma delta (γδ) T-cells possess multiple favorable anti-tumor characteristics, making them promising candidates to be used in cellular and combination therapies of cancer. They recognize malignant cells, infiltrate tumors, and depict strong cytotoxic and pro-inflammatory activity. Here, we focus on human Vy9Vδ2 T-cells, the most abundant γδ T-cell subpopulation in the blood, which are able to inhibit cancer progression in various models in vitro and in vivo. For therapeutic use they can be cultured and manipulated ex vivo and in the following adoptively transferred to patients, as well as directly stimulated to propagate in vivo. In clinical studies, Vy9Vδ2 T-cells repeatedly demonstrated a low toxicity profile but hitherto only the modest therapeutic efficacy. This review provides a comprehensive summary of established and newer strategies for the enhancement of Vy9Vδ2 T-cell anti-tumor functions. We discuss data of studies exploring methods for the sensitization of malignant cells, the improvement of recognition mechanisms and cytotoxic activity of Vy9Vδ2 T-cells. Main aspects are the tumor cell metabolism, antibody-dependent cell-mediated cytotoxicity, antibody constructs, as well as activating and inhibitory receptors like NKG2D and immune checkpoint molecules. Several concepts show promising results in vitro, now awaiting translation to in vivo models and clinical studies. Given the array of research and encouraging findings in this area, this review aims at optimizing future investigations, specifically targeting the unanswered questions.

Keywords: gamma delta T-cell, cancer immunotherapy, tumor metabolism, ADCC, NKG2D, immune checkpoints, programmed cell death protein 1, vascular endothelial growth factor

INTRODUCTION

Following the discovery in the 1980s, gamma delta (γδ) T-cells have become increasingly recognized as important players in natural host defense against infections and malignancies. Early evidence of an anti-tumor functionality of γδ T-cells came from the experiments in mice (1) and it is now well established (2). In humans, γδ T-cells can be found in various cancer tissue samples [e.g., melanoma (3, 4) and epithelial tumors (5–11)]. More recently, analysis of microarray data also described patterns of γδ T-cells in a large collection of malignancies (12) and a prior extensive gene expression study demonstrated that γδ T-cell infiltration into tumors represents a positive prognostic marker in many types of cancer (13). Offering some hints for a functional role in tumor rejection, γδ T-cell infiltration in melanoma, colorectal cancer, and lung tumors were found to be associated with lower stage and lack in metastasis. Additionally, γδ T-cells extracted from such cancer tissues were able to kill malignant cells in vitro (4, 14, 15). In cancer patients, γδ T-cells were also repeatedly found reduced or defective and depicted a diminished proliferative capacity (16–18).
and exhaustion (19–23). Patients with higher γδ T-cell count following allogenic stem cell transplantation for acute leukemia had a significant survival advantage (24). In connection with their suspected function in natural tumor defense, the utilization of γδ T-cells has become a promising concept in the field of cancer immunotherapy.

**Definition**

γδ T-cells express variables Vγ and Vδ chains (25, 26) as part of a T-cell receptor (TCR) complex that is structurally and functionally distinct from the major histocompatibility complex (MHC) binding TCR of αβ T-cells (27). In humans, it is feasible to further divide γδ T-cells into “Vδ2” and “non-Vδ2 cells,” the latter consisting of mostly Vδ1- and rarely Vδ3- or Vδ5-chain expressing cells. Despite unrestricted and the theoretically high combinatorial diversity (28), the Vδ2 chain is found preferentially paired with the Vγ9 chain (29). These Vγ9Vδ2 T-cells account for approximately 5% of peripheral blood T-cells, representing the dominant γδ T-cell subpopulation in this compartment in healthy human adults (30). Interestingly, the preferential appearance of Vγ9- and Vδ2-chains develops in the fetus (31), but the overall clonal repertoire of blood γδ T-cells is further contracting after birth (32). The latter is probably a response to a uniform stimulus, like a ubiquitous pathogen or conserved stress molecule (33).

**Functional Aspects**

Genetic and functional studies indicate that γδ T-cells have developed and act as an intermediate between the innate and the adaptive immune system. Features representative of an innate phenotype is their ability to mediate antibody-dependent cell-mediated cytotoxicity (ADCC) and phagocytosis and to rapidly react toward pathogen-specific antigens without prior differentiation or expansion (28). Notably, the gene expression signature of Vγ9Vδ2 T-cells was characterized as a hybrid of αβ and NK-cells (34). Typical characteristics of the adaptive immune system, found in γδ T-cells, are their capabilities for somatic recombination of receptor genes, memory formation (35), and professional antigen presentation (36). Unlike αβ T-cells, γδ T-cells respond directly to proteins and non-peptide antigens (37) and are therefore not MHC restricted (38). At least some γδ T-cell specific antigens display evolutionary conserved molecular patterns, found in microbial pathogens and “induced self-antigens,” which become upregulated by cellular stress, infections, and transformation (28). Following the observation on stimulatory effects of certain non-peptide mycobacterial components on Vγ9Vδ2 T-cells (39, 40), the responsible substances could be isolated and characterized and are commonly termed as phosphoantigens (PAGs) (41). We consider PAGs the primary trigger of Vγ9Vδ2 γδ T-cell activation and discuss them in greater detail in the following. However, Vγ9Vδ2 γδ T-cells may also respond to other antigens and ligands via TCR and (co-)receptors (42).

**Vγ9Vδ2 T-Cells in Cancer Immunotherapy**

Subsets of Vγ9Vδ2 T-cells can be defined analyzing the expression of surface markers (e.g., CD27, CD45RA, CCR7, and CD16) or regarding their dominant cytokine production and correlate with functional differences like proliferative capacity or cytotoxic potential (43, 44). It has been extensively demonstrated in vitro (45–55) and using in vivo models (22, 56–68) that γδ T-cells are able to recognize various tumor cells and exert strong anti-tumor effects. Tumor growth is inhibited via different mechanisms including the release of pro-inflammatory cytokines, granymes and perforin, and the engagement of apoptosis inducing receptors (69).

Several drugs and treatment concepts might improve the activity of Vγ9Vδ2 T-cells against cancer. Most candidates are still at a pre-clinical stage, some were tested in animal models, and very few went into clinical tests so far. Although Vδ1+ cells shown promising results pre clinically (70), all previous clinical trials focused on the usage of Vγ9Vδ2 T-cells. Reasons for the earlier therapeutic employment of Vγ9Vδ2 T-cells include their relatively high abundance in the peripheral blood and the possibility to efficiently culture them ex vivo or to stimulate and expand them in vivo using amino-bisphosphonates (N-BP) or synthetic PAGs (45), as discussed later.

Here, we divide the existing clinical studies according to the used strategy into two main groups: (1) in vivo activation (17, 18, 23, 71–74) and (2) adoptive cell transfer strategies (75–84). In the latter case, the adoptively transferred cells originally were extracted, activated, and cultured autologous blood cells. Varieties include the transfer of processed haploidentical cell preparations with subsequent in vivo stimulation (82), as well as local administration of cultured cells into the tumor or the peritoneal cavity (85, 86). Well organized and comprehensive analyses of the performed clinical studies involving γδ T-cells have recently been published by others (45, 87, 88) and an overview is given in Table 1.

**Outline**

Much has been learned by studying γδ T-cells from animals, especially those from mice. However, there are major distributional, structural, and functional differences between the species, especially the lack of Vγ9Vδ2 T-cells or functional homologs in mice (91, 92). In this review, we focus on human γδ T-cells, their anti-tumor capabilities, and strategies for improving the effectiveness of Vγ9Vδ2 T-cells in cancer immunotherapy. Current publications contain additional information on the topics not covered here, especially the biology of non-Vδ2 cells (93) and their role in cancer and cancer therapy (2). We also refer to more detailed literatures regarding the differences of rodent and human γδ T-cells (28), γδ T-cells acting as professional antigen-presenting cells (36), concerning B-cell help (94) and potential use as a vaccine (95), cell ontology (33), phylogenetic aspects (28, 42), genetically modified γδ T-cells (e.g., CARs) (96, 97), as well as molecular details of receptor signaling (98, 99). We discuss approaches especially that aim to sensitize target cells and the local interaction of tumor and effector cells in connection with the underlying mechanisms.

**TARGETING THE CELLULAR METABOLISM**

Survival and growth of cancer cells are connected to specific metabolic alterations which have been considered a distinctive
“hallmark of cancer” (100). Most prominent example of such adaptation is the “Warburg effect,” the preferential utilization of aerobic glycolysis by various tumor cells, described by Warburg in 1924 (101). Obvious elements of this phenotype are the inhibition of oxidative phosphorylation despite sufficient oxygenation, an elevated glucose consumption, and an increased production of lactic acid (LA). Changes in the tumor metabolism can be complex and besides glucose metabolism affect lipid and amino acid pathways (102). Correspondingly, our idea of Vγ9Vδ2 T-cell natural anti-tumor functions is based on their ability to distinguish normal and transformed cells due to their metabolic phenotype. In particular, they might recognize an adaptation is the “Warburg effect,” the preferential utilization of aerobic glycolysis by various tumor cells, described by Warburg in 1924 (101). Obvious elements of this phenotype are the inhibition of oxidative phosphorylation despite sufficient oxygenation, an elevated glucose consumption, and an increased production of lactic acid (LA). Changes in the tumor metabolism can be complex and besides glucose metabolism affect lipid and amino acid pathways (102). Correspondingly, our idea of Vγ9Vδ2 T-cell natural anti-tumor functions is based on their ability to distinguish normal and transformed cells due to their metabolic phenotype. In particular, they might recognize an "hallmark of tumorigenesis" rather than an outlier. In any case, several therapeutic concepts focus on Vγ9Vδ2 T-cells’ metabolic sensor and potent effector mechanisms.

### N-BPs and PAGs

Activation of Vγ9Vδ2 T-cells with PAGs and N-BPs is the most commonly used strategy for in vitro research and both in vivo stimulation as well as application of adoptive cell therapy. The potency of the individual PAg molecule to elicit response from Vγ9Vδ2 T-cells differs (108) and is especially high for microbial (E)-4-hydroxy-3-methyl-butenyl pyrophosphate (HMBPP), certain synthetic compounds like bromohydrin pyrophosphate (BrHPP) (109) or nucleotides derived from HMBPP (110). However, so far only BrHPP and N-BPs have been used clinically. N-BPs were found to trigger activation and expansion of Vγ9Vδ2 T-cells as well as their interferon-γ (IFN-γ) release (46, 111) and were later recognized as indirect acting PAGs (112). This class of substances is structurally related to direct PAgS, but acts by inhibition of farnesyl diphosphate synthase and the accumulation of upstream metabolites like the direct PAg IPP (113). In immunotherapy N-BPs serve a double purpose. First, they sensitize target cells, rendering many primarily resistant tumor

#### TABLE 1 | Clinical studies.

| Reference | Year | Disease | N | Reported outcome | Systemic therapy/comments |
|-----------|------|---------|---|------------------|--------------------------|
| Wilhelm et al. (18) | 2003 | MM, indolent, lymphomas | 19 | 16% PR, 16% SD | +PAM +IL-2/response correlates with in vitro expansion |
| Dieli et al. (23) | 2007 | HRPC | 18 | 16% PR, 27% SD | +ZOL +IL-2 +BrHPP +IL-2 |
| Bennouna et al. (73) | 2010 | RCC, GYN, GI-cancers | 28 | 42% SD | +ZOL +IL-2 +RTX |
| Laurent et al. (89) abstract only | 2010 | Follicular lymphoma | 45 | 26% CR, 18% PR | +ZOL +IL-2/response correlates with in vivo expansion |
| Meraviglia et al. (71) | 2010 | Breast cancer | 10 | 10% PR, 20% SD | +ZOL +IL-2 |
| Lang et al. (74) | 2011 | RCC | 12 | 16% SD | +ZOL +IL-2 |
| Kunzmann et al. (72) | 2012 | RCC, melanoma, AML | 21 | 16-42% SD | +ZOL +IL-2 |
| Pressey et al. (17) | 2016 | Neuroblastoma | 4 | 25% SD, 75% PD | +ZOL +IL-2 |

Aromatic, acute myeloid leukemia; BrHPP, bromohydrin pyrophosphate; Chem, chemotherapy; CR, complete remission; GI, gastrointestinal; GYN, gynecological; HCC, hepatocellular carcinoma; HRPC, hormone refractory prostate cancer; MM, multiple myeloma; N, number of patients; OS, overall survival; PAM, pamidronic acid; PD, progressive disease; PFS, progression free survival; PR, partial remission; RCC, renal cell carcinoma; RTX, rituximab; SD, stable disease; ZOL, zoledronic acid.
cells vulnerable to γδ T-cell mediated attack (114). Second, they induce expansion of γδ T-cells in vitro and in vivo. The degree of inhibition of farnesyl diporphosphate synthase thereby correlates well with important anti-tumor functions of Vγ9Vδ2 T-cells over various tumor cell lines (115). Apart from sensitization of tumor cells, N-BPs exert additional direct anti-neoplastic effects, like an increased production of toxic mevalonate pathway products and a decrease of essential downstream metabolites (113, 116).

Ex Vivo Culture and In Vivo Models

Potent natural and synthetic PAgs, like the patented drug BrHPP (termed as IPHI101 or Phosphostim®) can be used for effective in vitro (117) and in vivo (22, 75) expansion of VγVδ2 T-cells.

Protocols for ex vivo culture of human Vγ9Vδ2 T-cells vary regarding the culturing conditions, timing and dosage of used N-BPs or PAgs, and added co-stimulators like IL-2 (88, 118) and may result in different phenotypes and effector cell characteristics. Zoledronic acid (ZOL) is a potent N-BP and commonly used about 1 μM in vitro, a concentration also in the range of the peak plasma level following a single standard dose of 4 mg intravenously (88). Repetitive administration of exogenous IL-2 is commonly used as it drives proliferation of PAg stimulated VγVδ2 T-cells resulting in an increased yield (63, 67). Results of in vitro expansion are highly donor dependent and may also predict the respective in vivo expansion efficacy, which can be additionally restricted in cancer patients (18). Currently, an optimal dose of ZOL as well IL-2 has not been determined in vivo (88) and a recent study indicated that the efficacy of ZOL stimulation depends on drug concentration and duration of exposure with an individual optimum (67).

The ability to recognize the PAgs is linked to germline-encoded regions of the γδ TCR (119) and so far functionally only described in primates (120). Even though homologs sequences of human Vγ9 and Vδ2 genes were recently described in other species, such as alpaca and armadillo (121, 122). As wild type mice lack PAg-responding γδ T-cells the in vivo expansion of human Vγ9Vδ2 T-cells has been studied using xenograft mice (57, 123) or cynomolgus monkeys (59). Results from such models show that sensitizing tumor cells with N-BPs, combined with adoptive transfer of ex vivo expanded human Vγ9Vδ2 T-cells with or without exogenous IL-2 administration is feasible and induces moderate anti-tumor responses (58, 65, 66, 68, 124). The role for additional systemic application of N-BPs in context with adoptive cell transfer strategies remains uncertain. On one side it has been reported to promote engraftment of ex vivo stimulated and adoptively transferred human cells in mice (124), on the other side there are indications that repetitive application of these drugs in vivo induces Vγ9Vδ2 T-cells exhaustion (23, 71, 74).

Clinical Experience

One may speculate that the observed anti-tumor effects of N-BPs or high-dose IL-2 monotherapy as well as allogenic stem cell transplantation are influenced by γδ T-cells without being recognized as such (125–127). Implementation of clinical Vγ9Vδ2 T-cell studies benefited from the fact that side effects and pharmacological profiles of N-BPs and IL-2 monotherapy were already known. IL-2 is established as an effective treatment for several types of cancer for about 30 years (128) and N-BPs are widely used for osteoporosis, hypercalcemia, and the treatment of bone metastasis (125). The first prospective trial focusing on the in vivo stimulation of anti-tumor functions by γδ T-cells used the N-BP pamidronate acid (18), later studies the more potent ZOL (17, 23, 71, 72, 74) in combination with IL-2. These N-BPs have also been used to stimulate Vγ9Vδ2 T-cells ex vivo for adoptive cell therapy (76, 77, 80, 81, 83). Additionally, a few studies applying adoptive cell transfer included the systemic administration of ZOL with (79, 82) or without additional IL-2 (84). Taken together the clinical studies involving the use of N-BPs to increase the anti-tumor effects of Vγ9Vδ2 T-cells in different types of malignancies depicted a tolerable toxicity but revealed inconsistent responses and overall only a modest efficacy (compare Table 1).

Similarly, BrHPP was tested in early clinical studies with small success, for both ex vivo stimulation and consecutive adoptive transfer of cells in combination with IL-2 in metastatic renal cell carcinoma (75) and for in vivo stimulation targeting solid tumors (73). A strategy combining BrHPP stimulation and the tumor targeting antibodies rituximab (RTX) (89) is discussed separately.

Current Obstacles

Several reasons might explain the limited therapeutic effectiveness of both N-BPs and synthetic PAgs in vivo. Maybe most importantly N-BPs and synthetic PAgs lack cancer specificity regarding uptake or molecular targeting and also affect other cells. Also, N-BPs and BrHPP both have short plasma half-life periods (22, 67). BrHPP is quickly degraded by plasma phosphatases and common N-BPs cannot passively cross the plasma membrane, and is preferentially rooted to the bone due to their calcium binding characteristics (112). Cancer cells in other compartments are those that lack adequate active transport mechanisms might therefore not be affected. It is established that monocytes/macrophage type cells take up N-BPs via fluid endocytosis and induce activation of Vγ9Vδ2 T-cells (129, 130). Unfortunately ZOL also induces killing of human macrophages (131) and, additionally, uptake of N-BP by neutrophils impairs γδ T-cell proliferation via production of reactive oxygen species (132). Indeed treatment with N-BP can decrease circulating γδ T-cell count (133) and repetitive stimulation with BrHPP lead to progressive exhaustion of γδ T-cell activation and expansion in vivo (22). A new strategy to stimulate Vγ9Vδ2 T-cells and avoid exhaustion might be the application of an attenuated, live vaccine with genetically engineered metabolic profile that overproduces HMBPP. Adapting traits of a bacterial infection with Salmonella enterica indeed elicited a prolonged Vγ9Vδ2 T-cell immunity in monkeys (134). A different concept to increase N-BP concentration in the tumor tissue is to administer drugs (and ex vivo stimulated cells) locally (135). Nevertheless, this is not a working concept for systemic diseases. It also has to be taken into account that although commonly well tolerated, N-BPs and exogenous IL-2 have considerable and dose limiting toxicities, including inflammatory and cytokine reactions, osteonecrosis of the bone, and hypocalcemia (128, 136).
Modified PAgs and N-BPs

The development of new direct and indirect PAgs may overcome pharmacodynamic restrictions and improve clinical efficacy (112). Newly designed PAgs (137) and bisphosphonate prodrugs (138, 139) have chemically masked phosphate groups, allowing these compounds to enter cells without the need for active transmembrane transport (140) and should not accumulate in the bone. Following intracellular uptake they are converted to their active forms, which are potent stimulators of Vγ9Vδ T-cells and inhibit tumor cell lines toward γδ T-cell anti-tumor effects in vitro (138–140). Bisphosphonate prodrugs already depicted some effect in combination with adoptive cell transfer in an animal model of bladder carcinoma and human fibrosarcoma (138, 139).

Nano-technology based carriers for N-BP delivery (141) as well as lipophilic bisphosphonate (60, 142, 143) and synthetic nucleotide pyrophosphates (110) are additional pharmacotherapeutic strategies that may improve Vγ9Vδ T-cell immunotherapy in the future.

Butyrophilin 3A (BTN3A)

More recently, Butyrophilin 3A (BTN3A, CD277) was described as essential for γδ T-cell activation by direct PAgs (144, 145). BTN3A belongs to the important B7 family of co-stimulatory molecules (146) and consists of three isoforms: BTN3A1, BTN3A2, and BTN3A3. BTN3A2 differs as it lacks an intracellular B30.2 domain that is needed for Pag recognition. However, when using the mouse anti-human-CD277 antibody clone 20.1 directed against an extracellular domain, all BTN3A isoforms support Vγ9Vδ T-cell activation (144). The molecular details of signal transduction are a current research topic and matter of debate, especially regarding two different models: originally, the “antigen presenting model” by Vavassori et al. (145) assuming that CD277 and the TCR interact directly following Pag binding to an extracellular CD277 domain. Recent experimental evidence rather supports a second, so called “allosteric model” by Harly et al., postulating that PAgs interact with the intracellular B30.2 domain of CD277 (147) either directly (148) or indirectly (149, 150) and induce a conformational change that is transferred to the extracellular parts of the CD277 molecule (147, 151). Pag sensing may additionally involve molecules like Rh-GTPase (152) or Periplakin and is modulated by mechanisms enabling transmembranous Pag transport or via hydrolyzation of PAg by ecto-ATPase CD39 (106, 153).

Development of mouse anti-human-CD277 antibodies has been very useful in deciphering the activation processes of Vγ9Vδ T-cells (144, 154) and also holds therapeutic potential. The mode of action of these antibodies was proven to be downstream and independent of IPP (144, 149). Furthermore, activating anti-CD277 clone 20.1 has similar but not identical stimulatory capabilities compared with Pag stimulation (155) and might be restricted to certain Vγ9Vδ T-cells with specific complementarity-determining region sequences of the TCR (156). Still, anti-CD277 antibodies might outperform N-BPs or other metabolic sensitizers in target cells that fail to internalize drugs or which have decreased malonate pathway activity. It was shown that anti-CD277 antibodies enhance anti-tumor functions of Vγ9Vδ T-cells in vitro (144) and in a xenotransplant mouse model of human acute myeloid leukemia (AML) (157). We also observed that primary chronic lymphatic leukemia (CLL) cells are hardly affected by ZOL sensitization become lysed by Vγ9Vδ2 T-cells following their incubation with activating anti-CD277 antibody (158). Unfortunately, antibodies with a murine background seem inappropriate for clinical use and development of a humanized version or a human homolog of the clone 20.1 antibody has not been reported. A further drawback is the widespread expression of the CD277 molecule in human tissues (146, 159), which is why additional strategies for enhancement of selectivity might be required. One solution could be the development of antibody constructs combining both CD277 activating and tumor-antigen specificity.

Other Agents

Therapeutic specificity might also be achieved by targeting tumor cell specific metabolic alterations. Therefore, we tested whether the pyruvate dehydrogenase activator dichloroacetate (DCA) might improve Vγ9Vδ2 T-cell anti-tumor functions in vitro. DCA inhibits aerobic glycolysis, malignant cell proliferation and indirectly facilitates mitochondrial oxidative decarboxylation of pyruvate to acetyl-coenzyme A (160). Indeed, we found that DCA + ZOL treated leukemia cell lines induce higher IFN-γ production by Vγ9Vδ2 T-cells compared with ZOL treatment alone. We also suspected that DCA increases the supply of metabolites upstream of IPP and therefore increases PAg accumulation when combined with ZOL (161). Still, alternative explanations are possible as DCA decreases tumor cells’ LA production (160) and LA can directly inhibit several immune functions. Tumor LA efflux is, therefore, an attractive target and could be targeted by inhibition of lactate transporters and nonsteroidal anti-inflammatory drugs (NSAID) (101). Concerning potential anti-tumor effects of NSAIDs, the use of indomethacin as well as specific cyclooxygenase-2 inhibitors resulted in an increase of Vγ9Vδ2 T-cell dependent tumor cell lysis. If this observation is connected to LA release has not been investigated but was attributed to the inhibition of prostaglandin effects (162). Finally, the enzymes CD39 and CD73 that regulate ATP/adenosine balance and thereby the function of immune cells might represent interesting targets for immunotherapy (163). Here, CD39 might be of special interest in the context of Vγ9Vδ2 T-cell therapy as it was shown to be capable of PAg hydrolyzation (164).

Summary

Adaptive transfer of ex vivo cultured cells and various combinations of N-BPs, BrHPP, and IL-2 have demonstrated clinical effects but are rather disappointing compared to the promising pre-clinical results. The discrepancy suggests that the in vivo characteristics of stimulated Vγ9Vδ2 T-cells are still insufficiently understood. To overcome the current limitations, we need to learn more about differentiation and functionality of Pag activated γδ T-cells, its subpopulations and migration patterns. PAg and N-BPs with improved pharmacokinetics and potency are very promising new developments, but their toxicity profile and clinical effectiveness have yet to be established. A breakthrough
would be the development of PAg or N-BP analogs with strong molecular tumor cell specificity.

Beside these innovations, we should search for additional tumor-specific transport mechanisms and metabolic peculiarities. A good example for the exploitation of a “metabolic weak spot” in cancer is the use of asparaginase in acute lymphatic leukemia (165). We need to identify such targets in the context of γδ T-cell sensing and will hopefully be able to design specific and effective compounds at least for certain types of cancer. Finally, we should consider the metabolic needs of immune cells as well. They may also rely on mevalonate pathway products or upregulate aerobic glycolysis following activation (166) and therefore become negatively affected by certain therapeutic interventions.

TARGETING ACTIVATING AND INHIBITORY RECEPTORS

NKG2D and Its Ligands

In innate immune responses mediated by NK-cells, NKG2D serves as a primary activating receptor and ligand binding triggers cytotoxicity and cytokine production (167–169). In humans, one NKG2D homodimer assembles with four DAP10 adaptor proteins that become phosphorylated upon ligand binding and activation (170). Ligands from distinct families, the MHC class I polypeptide related sequence A (MICA) and B (MICB) and the cytomegalovirus UL16-binding protein (ULBP) family bind NKG2D even though they share little sequence similarity (171). The expression of NKG2D ligands (NKG2DL) is induced and upregulated primarily in tissues of epithelial origin, as a result of cellular stresses such as viral infection, malignant transformation, or classical heat shock (172, 173). All NKG2DLs are not functionally equivalent and can enable immune cells to recognize of a broad range of different types of infections and indicate malignant transformation in different tissues (170, 171, 174).

NKG2D is also expressed by γδ T-cells and provides important (co-)stimulatory signals in T-cell-mediated immune responses by amplifying T-cell cytokine production, proliferation, and cytotoxicity in vitro (52, 98, 169, 175). The NKG2D pathway is also relevant in the context of N-BP treatment and the expression of ULBP1 was found correlated with the sensitivity of AML blasts toward TCR-mediated killing by Vy9V82 T-cells (114). Additionally, the results of Wrobel et al. indicated that the NKG2D pathway is involved in anti-tumor effects of γδ T-cells against melanoma and various epithelial cancers (55).

MICA-Polymorphism and Soluble MIC (sMIC)

The general concept is that cell stress and transformation increase the expression of MICA antigens and activate immune cells via NKG2D. However, MICA is a highly polymorphic human stress antigen and Shaﬁ et al. showed that MICA coding sequence polymorphisms substantially affected RNA and protein expression (176). Some examined individuals showed better response to higher, others to lower MICA expression, and challenging the concept of an invariant direct correlation between stress molecule abundance and immune cell activation (176, 177).

Tumors also adopt evasion strategies, like shedding of free or the exosome form of MICA/MICB. These released molecules can inhibit immune effector cells due to interaction with NKG2D (178). Märtén et al. found elevated levels of sMIC in sera of patients with pancreatic carcinoma correlated with tumor stage. The cytotoxic response of immune toward tumor cells was found impaired with in the presence of high sMIC levels but restored by neutralization of sMIC (179).

Temozolomide (TMZ) and Other Chemotherapeutics

Glioblastoma multiforme (GBM) is an extremely aggressive brain tumor, which is not very sensitive to either classical chemotherapy or immunotherapeutic approaches. Lamb et al. showed that ex vivo expanded γδ T-cells recognize malignant glioma via NKG2D and lyse glioma cell lines and primary GBM specimens. Additionally TMZ, a DNA methylating chemotherapeutic agent licensed for GBM therapy, increased NKG2D also on TMZ-resistant glioma cells. They also demonstrated that immune effector cells can be genetically modiﬁed to resist the toxicity of TMZ without changing their phenotype or their cytotoxicity against GBM target cells (180). Similarly, Chitadze et al. investigated the NKG2D system in different GBM cell lines and conﬁrmed that TMZ increased the cell surface expression of NKG2D and sensitizes GBM cells to γδ T-cell mediated lysis. TMZ might therefore enhance the potential of adoptive transfer of ex vivo expanded γδ T-cells for glioblastoma treatment (181, 182).

Dacarbazime is a cytotoxic drug used for treatment of Hodgkin’s lymphoma and melanoma. Although dacarbazime does not directly affect immune cells, it triggers the upregulation of NKG2D on tumor cells, leading to NK-cell activation and IFN-γ secretion in mice and humans (183). Apart from TMZ and dacarbazime, studies suggest that other chemotherapeutics, like ﬂuorouracil, doxorubicin, or vincristine sensitize tumor cell lines toward a NKG2D-dependent cytotoxic activity of Vy9V82 T-cell (184, 185). This could be a target cell or drug specific phenomenon as we were unable to boost γδ T-cell induced lysis of several leukemia cell lines with other cytostatic drugs (186).

Bortezomib and Epigenetic Drugs

Niu et al. reported that multiple myeloma (MM) cells can be sensitized toward killing by γδ T-cells and NK-cells using low-dose bortezomib. Additionally, bortezomib increases the expression of NKG2D and induces apoptosis of MM-cells, but not γδ T-cells and NK-cells (187). Treatment with 5-azacytidine, its derivate decitabine or histone deacetylase inhibitors may also increase the expression of NKG2D in different types of malignancies prompting Bhat et al. to consider those epigenetic drugs as a promising approach in γδ T-cell immunotherapy (188). Suzuki et al. evaluated possible additive effects of valproic acid (VPA), a histone deacetylase inhibitor, on γδ T-cell mediated cytotoxicity against bladder cancer cell lines TCCSUP and 253J (189). VPA did increase expression of NKG2D and sensitivity toward cytolyis by γδ T-cells for both cancer cell types, whereas ZOL pre-treatment was only effective against TCCSUP. 253J cells were preferentially engaged via NKG2D-NKG2DL interaction, while TCCSUP cells were mainly recognized through the γδ TCR (189). Chávez-Blanco et al. showed that hydralazine in combination...
with VPA increase the expression of MICA and MICB ligands by target cells, as well as NK-cell cytotoxicity via NKG2D. Additionally it reduces the shedding of MIC molecules to the supernatant (190). Satwani et al. incubated acute lymphoblastic leukemia and non-Hodgkin lymphoma cell lines for 24 h with 10 ng/mL of romidepsin (191). They demonstrated an approximately 50- to 1,300-fold increase in the number of cells positive for the surface expression of MICA/B in these cell lines. They further demonstrated a significant increase in NK-cell-mediated in vitro cytotoxicity (191).

Inhibitory Receptors

The development of immune checkpoint inhibitors targeting the cytotoxic T-lymphocyte-associated Protein 4 (CTLA4) or programmed cell death protein 1 (PD-1) and its ligand (PD-L1) has substantially extended the possibilities of immunotherapy. These substances are able to induce enduring remissions in a considerable subset of patients with treatment refractory types of cancer, for example melanoma, non-small cell lung cancer, and Hodgkin's lymphoma (192). Considering their clinical significance, relatively little is known about the role of γδ T-cells in immune checkpoint therapy and also regarding the role of inhibitory axes for γδ T-cell biology.

Programmed Cell Death Protein 1

Programmed cell death protein 1 is a key inhibitory receptor in inflammation, responsible for induction of tolerance, and immunosuppression in cancer (193). Following interaction with its ligands programmed death-ligand 1/2, the PD-1 receptor inhibits TCR and PI3K/AKT signaling and decreases proliferation and IL-2 release (194). It is interesting that both the PD-Ls and the CTLA4 ligands (CD80 and CD86) are members of the B7 family of proteins and therefore interrelated to BTN3A/CD277. Several types of malignancies have a relevant susceptibility to therapeutic PD-1/PD-L1 blockade, but it is barely predictable which individual patient will respond. The initially assumed direct relationship between tumor cell expression of PD-Ls and response rate following therapeutic PD-1 blockade might not be universally valid and the strength of PD-1 dependent immunosuppression is influenced by the topographic organization of the tumor microenvironment (195).

An early in vitro study addressed the expression profile and functionality of PD-1/PD-L1 in γδ T-cells following stimulation with HMBPP and suggested that the PD-1/PD-L1 axis is important for regulation of anti-tumor mechanisms of γδ T-cells (196). Later it was found that PD-1 expression is more frequent on Vδ1, compared with Vδ2 T-cells (197) and equably distributed over several functionally distinctive subsets of Vγ9Vδ2 T-cells (44). A report that ex vivo cultivated Vδ2 T-cells depict stable, low cell surface expression of PD-1 following adoptive transfer (198) might fit the observations that PD-1 is only temporarily upregulated following in vitro stimulation as it has been reported both for HMBPP and ZOL (196, 198). Vδ2 T-cells derived from neonates may behave differently as they depict prolonged PD-1 expression following activation and function as a regulator of tumor necrosis factor-α (TNF-α) production and cell degranulation, both being part of fetal inflammatory response (199).

Programmed cell death protein 1 expression might contribute to insufficient expansion of Vγ9Vδ2 T-cells in cancer patients, as a diminished response to PAg stimulation was demonstrated in bone marrow derived Vγ9Vδ2 T-cells from patients with MM. Such cells depicted a significantly increased PD-1 expression and were located in proximity to PD-L1+ MM-cells and myeloid-derived suppressor cells (200). Additional treatment with PD-1 antibody resulted in a twofold increase in proliferative response and an increased mobilization of CD107a following ZOL stimulation in vitro (200). Beside the bone marrow of MM patients, PD-1 positive γδ T-cells were also found in neuroblastoma infiltrated bone marrow (201).

Other Inhibitory Receptors

Alongside PD-1 several other inhibitory molecules are currently investigated regarding their function in limiting anti-tumor responses and potential therapeutic prospects (202). This is of special interest as there are indications for compensatory upregulation of alternative inhibitory receptors during anti-PD-1 therapy (203). Examples are the B- and T-lymphocyte attenuator (BTLA), CTLA4, T-cell immunoglobulin and mucin-domain containing-3 (TIM-3), and lymphocyte activation gene-3 (LAG-3) and their respective ligands.

B- and T-lymphocyte attenuator was suggested to inhibit late phases of immune reactions and has structural and functional similarities to PD-1 and CTLA4 (204). It is expressed on Vγ9Vδ2 T-cells and engagement by its ligand, the herpesvirus entry mediator, reduced activation, proliferation, and anti-lymphoma response (205). Differing from PD-1 expression kinetics (196, 198), BTLA is initially downregulated following stimulation with PAgS but upregulated upon IL-7 treatment (205).

Compared with PD-1 and BTLA, even less is known concerning the functional implications of CTLA4, LAG-3, and TIM-3 on γδ T-cells. Melanoma patients with a higher ratio of Vδ1 to total γδ T-cells had poorer overall survival and vice versa higher frequencies of Vδ2 cells were associated with longer survival in a study using CTLA4 inhibitory antibody ipilimumab (16). Expression of LAG-3 indicates inhibition of PD-1 + T-cells in the tumor tissue and poorer prognosis in follicular lymphoma (206). From studies examining distinctive T-cell populations, we know that CTLA4 can inhibit T-cell activity via signaling mechanisms distinctive from PD-1 (207), but we still lack mechanistic studies conclusively demonstrating CTLA4 expression and function for Vγ9Vδ2 T-cells. In women with pre-eclampsia γδ T-cells with low TIM-3 expression depict a higher IFN-γ production (208) and in the context of malaria infection a high TIM-3 level was found correlated with reduced pro-inflammatory cytokine production (209). Similar to anti-PD-L1 antibodies, the inhibition of the TIM-3 ligand galactine-9 that is expressed by γδ T-cells, increases tissue infiltration by αβ T-cells in a pancreatic tumor model (5).

Summary

The referred data provide interesting prospects to enhance immunotherapy by means of modulating the expression of NKG2DL. Even though several of the referred effects were shown for NK-cells, these strategies might also apply for sensitizing tumor...
cells toward γδ T-cell dependent cytotoxicity. Negative aspects like possible adverse effects on immune cell functionality or tumor escape mechanisms like sMIC and MICA-polymorphism need to be considered in future studies.

The physiological relevance of the currently known inhibitory receptors for γδ T-cells biology remains vague and additional observational and experimental studies are required. Based on the current evidence we assume that PD-1 is important for regulation of γδ T-cell functionality under specific conditions only, for example in an immunosuppressive tumor microenvironment. In inflammation and in the tumor microenvironment, γδ T-cells can become inhibited via PD-1 and also inhibit other PD-1 + immune cells via PD-L1 expression (5, 210). However, inhibitory effects of PD-1 may be overridden upon strong (co-) stimulation, for example via the TCR or with IL-2. Beside the local tissue distribution of receptors and ligands, expression kinetics are important to understand the function of the inhibitory receptors for immune homeostasis. Unfortunately, many studies do not distinguish whether tissue infiltrating T-cells are αβ or γδ T-cells in the first place. Combination therapy of adoptive transfer or in vivo stimulation of γδ T-cells with PD-1, PD-L1, CTLA4, or BTLA antibodies therefore seems feasible but the pre-clinical rational is currently not well established.

ADCC AND ANTIBODY CONSTRUCTS

Cytotoxicity of γδ T-cells against target cells can be significantly enhanced using specific monoclonal antibodies (mAbs) that induce ADCC. ADCC of γδ T-cells is thought to depend on Fc-γ receptor III (CD16) as it has been demonstrated that anti-CD19 antibody triggered CD107a, IFN-γ, and TNF-α expression is correlated to the amount of CD16+ γδ T-cells in an in vitro cytotoxicity assay (211). Furthermore, γδ T-cell mediated ADCC increases with higher numbers of CD16+ γδ T-cells (212) and was found inhibited with CD16 blocking antibodies (213). CD16 expression is usually low in unstimulated γδ T-cells, but increases following activation, for example with PAg (213, 214).

B-Cell Malignancies

Rituximab

Several lymphoma and B-cell lineage leukemia subtypes were studied using stimulated γδ T-cells in combination with monoclonal anti-CD20 antibodies (212–216). Tokuyama et al. found RTX to increase the killing of several lymphoma cell lines and to improve ADCC of γδ T-cells against CLL and autologous follicular lymphoma cells (213). Furthermore, BrHPP stimulated γδ T-cells demonstrated stronger CD107a expression and increased ADCC toward individual B-cell lymphoma cell lines and patient CLL cells in combination with anti-CD20 antibodies (214). One single clinical phase I/IIa study used RTX plus BrHPP and IL-2 for in vivo stimulation of γδ T-cells in patients with relapsed follicular lymphoma (89). Altogether, 45 patients were treated according to protocol and the treatment was generally well tolerated, with low grade pyrexia being the most common side effect (89). Despite the 45% overall response rate (26% complete response) (89), it seems like development of BrHPP containing therapies is no longer pursued by the company in charge.

Second Generation Anti-CD20 Antibodies and Anti-CD52

The newer anti-CD20 antibodies ofatumumab and obinutuzumab were also tested regarding the efficacy inducing ADCC in connection with γδ T-cells (215). Obinutuzumab is an Fc engineered type II monoclonal antibody (217) and causes an increased secretion of perforin and IFN-γ compared to RTX and ofatumumab. Accordingly, the highest ADCC against B-cell lymphoma cell lines and primary follicular lymphoma cells was found for obinutuzumab (215). Similar to anti-CD20 antibodies, Gartner-Dardenne found alemtuzumab, an anti-CD52 antibody, to increase γδ T-cell dependent ADCC against lymphoma cell lines (214).

Solid Tumors

Breast Cancer

Two groups investigated whether the human epidermal growth factor receptor 2 (HER2/neu) specific antibody trastuzumab enhances γδ T-cell dependent ADCC toward breast cancer cell lines in vitro (63, 213). The addition of trastuzumab greatly increased lysis of HER2/neu overexpressing cell lines, whereas there was no change in a HER2/neu negative cell line (213). The extent of ADCC was increased with higher density of HER2/ neu expression. Anti-tumor activity was confirmed in an animal model with SCID Beige mice. Here, the tumor growth was more efficiently inhibited by a combination treatment with γδ T-cells and trastuzumab compared to treatment with trastuzumab or γδ T-cells alone (63).

Neuroblastoma and Ewing’s Sarcoma

Both in neuroblastoma and in Ewing's sarcoma, the disialoganglioside specific antibody ch14.18/CHO increased γδ T-cell mediated ADCC in vitro (124, 218). This finding was confirmed in an advanced immunodeficient mouse model, where ex vivo stimulated and adoptively transferred γδ T-cells with simultaneous administration of ch14.18/CHO antibody impaired tumor growth more efficiently than single antibody or sole γδ T-cells treatment (124).

Antibody Constructs and Nanobodies

Antibody constructs have been studied in both lymphoma and solid tumor models. Seidel et al. used the Fc modified CD19 antibody 4G7SDIE as a backbone for bispecific CD19-CD16 and CD19-CD3 antibody constructs (211). Although no direct comparison between unaltered antibodies and the antibody constructs was made, the constructs proved active in inducing cytotoxic reactions by γδ T-cells. Schiller et al. went one step further and engineered a so called “single chain triplebody,” called SPM-1, that consists of three single chain antibody fragments (CD19-CD19-CD16) (219). Indeed, SPM-1 induced a higher lysis compared to 4G7SDIE. A comparable approach is a recombinant construct consisting of a CD20 single-chain fragment variable (scFv) linked to MICA or ULBP2 which enhances cytotoxicity of stimulated γδ T-cells against CD20+ lymphoma cell lines and primary CLL cells via NKG2D (220). Oberg et al. designed two bispecific antibodies that bind either CD3 or the Vγ9 TCR-chain on γδ T-cells and Her2/neu expressed proteins.
Figure 1: Continued

**Strategy**

1. Direct increase of PAg
2. Indirect increase of PAg
3. Improve recognition via NKG2DL
4. Antibody dependent
5. Inhibit immunosuppressive molecules
6. Antagonize inhibitory receptors
7. Decrease pro-tumor molecules
8. Modulate cytokine signaling

**Example**

- a) PAg b) N-BPs
- TMZ
- mAbs and constructs
- NSAID
- anti-PD-1 mAb
- anti-VEGF mAb
- IL-2
by pancreatic adenocarcinoma cells (221). Both antibodies enhanced γδ T-cell mediated cytotoxicity and adoptive transfer of γδ T-cells combined with \([\text{HER2}]2\times\gamma9\) antibody therapy inhibited growth of pancreatic cancer in a SCID Beige mouse model (221). Furthermore, Hoh et al. demonstrated improved anti-tumor effects against hepatocellular carcinoma and hepatoblastoma cells with MT110, an epithelial molecule EpCAM/CD3 bispecific T-cell engager antibody, compared to the anti-EpCAM antibody adecatumumab (222). Zhang et al. utilized a bifunctional fusion protein (anti-CD3 single-scFV/-NKG2D) that binds NKG2DL+ tumor cells and recruits and stimulates T-cells via CD3 (223). This fusion protein was able to stimulate IFN-γ production by T-cells, increased cytotoxic reaction against NKG2DL+ tumor cells in vitro and promoted survival in a murine lymphoma model (223).

Another innovative approach is the use of so called nanobodies, a single heavy chain fragment. They bind highly selective to the Vγ9Vδ2 chain and elicited either inhibiting or activating reactions from γδ T-cells (224, 225). Although no data on cytotoxic features against tumor cells are available, it seems to be a promising approach to a selective modulation of Vγ9Vδ2 T-cell activity.

**Summary**

Monoclonal antibodies combine high target specificity with a favorable toxicity profile, but often depict limited activity when used as single agents. Therefore, combination with γδ T-cells is a promising concept for cancer immunotherapy. There are many mAbs for various hematological and non-hematological malignancies in clinical use already and more are currently in pre-clinical or early clinical development. Several such mAbs are promising combination partners as they show a uniformly strong enhancement in γδ T-cell mediated cytotoxicity. However, results of the only clinical study in this regard, which used RTX plus in vivo stimulation of γδ T-cells fell short of expectations. With the advent of new and Fc optimized antibodies and more specifically stimulated γδ T-cells, a higher effectiveness might be achievable.

**COUNTERACTING PRO-TUMOR EFFECTS**

The local interplay of malignant, immune and stroma cells via direct cellular interactions and soluble factors characterizes the tumor microenvironment. Under these conditions, infiltrating immune cells can be suppressed and therapeutic activation may even unfold unintended tumor-promoting effects. Beside macrophages and regulatory T-cells (70, 96), IL-17-producing γδ T-cells (γδ T17 cells) are often suggested as important local mediators of tumor progression as repetitively demonstrated in animal models (226–228). It is possible to induce IL-17 production in human cells γδ T-cells in vitro (229) and γδ T17 cells were described in the human tumor microenvironments (7, 230) where they have been found inversely correlated with survival and associated with increased stage in breast (6) and colorectal cancer (7). It is important to note that not all studies differentiated between Vδ2 and non-Vδ2 cells or other γδ T-cell subclasses but it seems likely that both, Vδ2 but mainly the non-Vδ2 cells produce IL-17 (7). Direct proof is lacking, but it has been suggested that γδ T-cells can be changed toward an IL-17 producing phenotype by means of the tumor microenvironment (229, 231). Beside IL-17, vascular endothelial growth factor (VEGF) and granulocyte-macrophage colony-stimulating factor are predominately recognized as pro-tumor factors in the microenvironment, but it may not be reasonable to attribute an exclusive pro-or anti-tumor effect to any signal protein, cytokine, cell type or receptor-ligand interaction. For example VEGF facilitates neo-angiogenesis and immunosuppressive effects (232, 233) but also promotes tissue trafficking of different leukocytes (234, 235). The use of immunostimulatory drugs can induce unexpected changes in VEGF levels, as we observed an increase in VEGF serum levels following treatment with ZOL plus low-dose IL-2 in cancer patients (72). Pro-angiogenic factors like VEGF play an important pro-tumor role and predict poor clinical response to certain types of immunotherapy (72, 236). We recently described that following stimulation with IL-2 local lymphocyte-monocyte interactions regulate VEGF homeostasis via release of VEGF and soluble VEGF receptor 1 in a time-dependent manner in vitro (237). Potential pro-tumor factors and cells could be additionally targeted in combination with γδ T-cell therapy, for example via VEGF or IL-17 antagonists. VEGF antibodies are already widely used as cancer therapeutics making clinical studies investigating such a combination therapy feasible. The modest clinical effects of anti-angiogenic strategies call for a more fundamental analysis of VEGF signaling in the tumor microenvironment and the contribution of immune cells to these processes. The same also applies for other factors like IL-17.

Finally, both pro- and anti-tumor effects are mediated locally, as a consequence the in vivo efficacy of Vγ9Vδ2 T-cells will depend on their ability to infiltrate into the relevant tissues. Unfortunately we have little information concerning the capacity of activated γδ T-cells to reach the tumor in humans. One single clinical study demonstrated that autologous, ex vivo stimulated γδ T-cells predominately migrate to lung, liver and...
REFERENCES

1. Girardi M, Oppenheim DE, Steele CR, Lewis JM, Glusac E, Filler R, et al. Regulation of cutaneous malignancy by gammadelta T cells. Science (2001) 294(5542):605–9. doi:10.1126/science.1063916

2. Silva-Santos B, Serre K, Norell H. [Gamma][delta] T cells in cancer. Nat Rev Immunol (2015) 15(11):683–91. doi:10.1038/nri3904

3. Bialasiewicz AA, Ma JX, Richard G. Alpha/beta- and gamma/delta TCR(+) lymphocyte infiltration in necrotising choroidal melanomas. Br J Ophthalmol (1999) 83(9):1069–73. doi:10.1136/bjo.83.9.1069

4. Cordova A, Toia E, La Mendola C, Orlando V, Meraviglia S, Rinaldi G, et al. Characterization of human gammadelta T lymphocytes infiltrating primary malignant melanomas. PLoS One (2012) 7(11):e49987. doi:10.1371/journal.pone.0049987

5. Daley D, Zambrinis CP, Seifert L, Akkad N, Mohan N, Werba G, et al. Gammadelta T cells support pancreatic oncogenesis by restraining alpha/beta T-cell activation. Cell (2016) 166(6):1485–99.e15. doi:10.1016/j.cell.2016.07.046

6. Ma C, Zhang Q, Ye J, Wang F, Zhang Y, Wevers E, et al. Tumor-infiltrating gammadelta T lymphocytes predict clinical outcome in human breast cancer. J Immunol (2012) 189(10):5029–36. doi:10.4049/jimmunol.1201892

7. Wu P, Wu D, Ni C, Ye J, Chen W, Hu G, et al. Gammadelta+T cell promotes the accumulation and expansion of myeloid-suppressor cells in human colorectal cancer. Immunity (2014) 40(5):785–800. doi:10.1016/j.immuni.2014.03.013

8. Zocchi MR, Ferrarini M, Migone N, Casaroli G. T-cell receptor V delta gene usage by tumour reactive gammadelta T lymphocytes infiltrating human lung cancer. Immunology (1994) 81(2):234–9.

9. Bas M, Bier H, Schirklau K, Frieb-Hoffmann U, Scheckenbach K, Balz V, et al. Gamma-delta T-cells in patients with squamous carcinoma of the head and neck. Oral Oncol (2006) 42(7):691–7. doi:10.1016/j.oraloncology.2005.11.008

10. Groh V, Rhinehart R, Secrist H, Bauer S, Grabstein KH, Spies T. Broad tumor-associated expression and recognition by tumor-derived gammadelta T cells of MICA and MICB. Proc Natl Acad Sci USA (1999) 96(12):6879–84. doi:10.1073/pnas.96.12.6879

11. Oberg HH, Peipp M, Kellner C, Sebens S, Krause S, Petrick D, et al. Novel bispecific antibodies increase gammadelta T-cell cytotoxicity against pancreatic cancer cells. Cancer Res (2014) 74(5):1349–60. doi:10.1158/0008-5472.CAN-13-0675

12. Tosolini M, Pont F, Poupot M, Vergez F, Nicolai-Travers ML, Vermijlen D, et al. Assessment of tumor-infiltrating TCR gamma/delta2 gammadelta lymphocyte abundance by deconvolution of human cancers microarrays. Oncoimmunology (2017) 6(3):e1284723. doi:10.1080/20162402X.2017.1284723

13. Gentles AJ, Newman AM, Liu CL, Bateman SV, Feng W, Kim D, et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med (2015) 21(8):938–45. doi:10.1038/nm.3909

14. Meraviglia S, Lo Presti E, Tosolini M, La Mendola C, Orlando V, Todaro M, et al. Distinctive features of tumor-infiltrating gammadelta T lymphocytes in human colorectal cancer. Oncoimmunology (2017) 6(10):e1347742. doi:10.1080/20162402X.2017.1347742

15. Zocchi MR, Ferrarini M, Rugari C. Selective lysis of the autologous tumor by delta TCS1+ gamma/delta+ tumor-infiltrating lymphocytes from human lung carcinomas. Eur J Immunol (1990) 20(12):2685–9. doi:10.1002/eji.1830201224

16. Wistuba-Hamprecht K, Martens A, Hachnel K, Geukes Foppen M, Yuan J, Postow MA, et al. Proportions of blood-borne Vdelta1+ and Vdelta2+ T-cells are associated with overall survival of melanoma patients treated with ipilimumab. Eur J Cancer (2016) 64:116–26. doi:10.1016/j.ejca.2016.06.001

17. Pressey JG, Adams J, Harkins L, Kelly D, You Z, Lamb LS Jr. In vivo expansion and activation of gammadelta T cells as immunotherapy for refractory neuroblastoma: a phase 1 study. Medicine (Baltimore) (2016) 95(39):e4909. doi:10.1097/MD.0000000000004909

18. Wilhelm M, Kunzmann V, Eckstein S, Reimer P, Weissinger F, Ruediger T, et al. Gammadelta T cells for immune therapy of patients with lymphoid malignancies. Blood (2003) 102(1):200–6. doi:10.1182/blood-2002-12-3665

19. Yi Y, He HW, Wang JX, Cai XY, Li YW, Zhou J, et al. The functional impairment of HCC-infiltrating gammadelta T cells, partially mediated by regulatory T cells in a TGFbeta- and IL-10-dependent manner. J Hepatol (2013) 58(5):977–83. doi:10.1016/j.jhep.2012.02.015

CONCLUSION

The results from pre-clinical research and individual clinical responses to gammadelta T-cell therapy encourage to carry on studying their T-cell biology and aim to improve their T-cell related anti-cancer therapies. The question is, how the manifold observations on cellular mechanisms can help to establish better anti-cancer strategies and which drugs have an actual translational perspective. An overview on current gammadelta T-cell dependent therapeutic strategies and immune cell interactions in the tumor microenvironment is given in Figure 1. The use of mAb in combination with activated gammadelta T-cells is strikingly effective in vitro. Still the results from in vivo experiments did not always keep up with such expectations and the results of the only clinical trial did not prove superior to mAb monotherapy. We will need a thorough understanding of Vγ9Vδ2 T-cell subpopulations and their functional differences and must learn how to influence differentiation and prevent exhaustion. Our knowledge regarding the migration and tissue infiltration of Vγ9Vδ2 T-cells in vivo is still sparse, as is the understanding of pro- and anti-tumor mechanisms and cellular interactions in the tumor microenvironment. The establishment of better models could help deciphering those local and time-dependent processes. While the relevance of metabolic changes for immune and cancer cell function is now increasingly acknowledged, we need to learn how immune cells detect and respond to such changes. Reactivity to PAg by Vγ9Vδ2 T-cell may serve as an example, but we should be able to target even more specific tumor characteristics with cellular or combination therapy in the future.

AUTHOR CONTRIBUTIONS

TH wrote the manuscript and prepared the figure. MS and DP drafted sections and edited the manuscript. MW structured and edited the manuscript. All authors read and approved the submitted version.

FUNDING

TH and DP were supported by “Verein Hilfe für Krebskranke e.V.” and a scholarship from the “W. Lutz Stiftung.”
20. Gaafar A, Aljurfi MD, Al-Sulaiman A, Iqniebi A, Manogaran PS, Mohamed GE, et al. Defective gammadelta T-cell function and granzyme B gene polymorphism in a cohort of newly diagnosed breast cancer patients. Exp Hematol (2009) 37(7):838–48. doi:10.1016/j.exphem.2009.04.003

21. Zheng BJ, Ng SP, Chua DT, Sham JS, Kwong DL, Lam CK, et al. Peripheral gamma delta T-cell deficit in nasopharyngeal carcinoma. Int J Cancer (2002) 99(2):213–7. doi:10.1002/jic.10326

22. Sicard H, Ingoure S, Luciani B, Serraz C, Fournie JJ, Bonneville M, et al. Evolution of the V, D, and J gene segments used in the primate gammadelta T-cell receptor reveals a dichotomy of conservation and diversity. Proc Natl Acad Sci U S A (2011) 108(29):E332–40. doi:10.1073/pnas.1105105108

23. Munoz-Ruiz M, Perez-Flores V, Garcillan B, Guardo AC, Mazariegos MS, et al. Differentiation of effector/memory Vdelta2 T cells and migratory routes in lymph nodes or inflammatory sites. J Exp Med (2003) 198(3):391–7. doi:10.1084/jem.20030235

24. Ravens S, Schultze-Florey C, Raha S, Sandrock I, Drenker M, Oberdorfer L, et al. Identification and sequence of a fourth human T cell antigen receptor chain. Nature (1987) 330(6148):569–72. doi:10.1038/330569a0

25. Hayday AC, Saito H, Gillies SD, Kranz DM, Tanigawa G, Eisen HN, et al. Structure, organization, and somatic rearrangement of T cell gamma genes. Cell (1985) 40(2):239–69. doi:10.1016/0092-8674(85)90140-6

26. Loh EY, Lanier LL, Turck CW, Littman DR, Davis MM, Chien YH, et al. Structure, organization, and somatic rearrangement of T cell gamma genes. Cell Immunol (2003) 225(2):191–217. doi:10.1016/s0092-8674(03)00041-0

27. Munoz-Ruiz M, Perez-Flores V, Garcillan B, Guardo AC, Mazariegos MS, et al. Defective gammadelta T-cell function and granzyme B gene polymorphism in a cohort of newly diagnosed breast cancer patients. Exp Hematol (2009) 37(7):838–48. doi:10.1016/j.exphem.2009.04.003

28. Kazen AR, Adams EJ. Evolution of the V, D, and J gene segments used in the primate gammadelta T-cell receptor reveals a dichotomy of conservation and diversity. Proc Natl Acad Sci U S A (2011) 108(29):E332–40. doi:10.1073/pnas.1105105108

29. Godder KT, Henslee-Downey PJ, Mehta J, Park BS, Chiang KY, Abhyankar S, et al. Characterization of the human gammadelta T-cell receptor and the gammdelta T-cell deficit in nasopharyngeal carcinoma. J Immunol (2009) 182(11):7287–96. doi:10.4049/jimmunol.0804288

30. Corvaisier M, Moreau-Aubry A, Wessels JT, Niethammer D, Handgretinger R, Human gammadelta T lymphocytes exert natural and IL-2-induced cytotoxicity to neuroblastoma cells. J Immunother (2000) 23(5):536–48. doi:10.1097/00002371-200009000-00004

31. Pauza CD, Cairo C. Evolution and function of the TCR Vgamma9 chain in CD8+ T lymphocytes. J Immunol (2009) 182(11):7287–96. doi:10.4049/jimmunol.0804288

32. Dimova T, Brouwer M, Gosselin F, Tassignon J, Leo O, Donner C, et al. Differentiation of effector/memory Vdelta2 T cells and migratory routes in lymph nodes or inflammatory sites. J Exp Med (2003) 198(3):391–7. doi:10.1084/jem.20030235

33. Pont F, Familiades J, Déjean S, Fruchon S, Cendron D, Poupot M, et al. The recognition by human V gamma 9/V delta 2 T cells of a GroEL homolog on Daudi Burkitt's lymphoma cells. Science (1995) 264(5156):267–70. doi:10.1126/science.8146660

34. Fisher JP, Poccia F, Lipp M, Sireci G, Caccamo N, Di Sano C, et al. Differentiation of effector/memory Vdelta2 T cells and migratory routes in lymph nodes or inflammatory sites. J Exp Med (2003) 198(3):391–7. doi:10.1084/jem.20030235

35. Liu Z, Guo BL, Gehrs BC, Nan L, Lopez RD. Ex vivo expanded human Vgamma9Vdelta2+ gammadelta T cells mediate innate antitumor activity against human prostate cancer cells in vitro. J Urol (2005) 173(5):1552–6. doi:10.1016/j.juro.2005.01.035

36. Todaro M, D’Asaro M, Caccamo N, Lovino F, Francipane MG, Meraviglia S, et al. Efficient killing of human colon cancer stem cells by gammadelta T lymphocytes. J Immunol (2009) 182(11):7287–96. doi:10.4049/jimmunol.0804288

37. Wrobel P, Shojaei H, Schittek B, Gieseler F, Wollenberg B, Kalthoff H, et al. Recognition by human V gamma 9/V delta 2 T cells of a GroEL homolog on Daudi Burkitt's lymphoma cells. Science (1995) 264(5156):267–70. doi:10.1126/science.8146660

38. Wrobel P, Shojaei H, Schittek B, Gieseler F, Wollenberg B, Kalthoff H, et al. Recognition by human V gamma 9/V delta 2 T cells of a GroEL homolog on Daudi Burkitt's lymphoma cells. Science (1995) 264(5156):267–70. doi:10.1126/science.8146660
57. Wang L, Kamath A, Das H, Li L, Bukowski JF. Antibacterial effect of human V gamma 2V delta 2 T cells in vivo. J Clin Invest (2001) 108(9):1349–57. doi:10.1172/JCI12503

58. Kabelitz D, Wesch D, Pitters E, Zoller M. Characterization of tumor reactivity of human V gamma 9V delta 2 gamma delta T cells in vitro and in SCID mice in vivo. J Immunol (2004) 173(11):6767–76. doi:10.4049/jimmunol.173.11.6767

59. Casetti R, Perretta G, Taglioni A, Mattei M, Colizzi V, Dieli F, et al. Drug-induced expansion and differentiation of V gamma 9V delta 2 gamma delta T cells in vivo: the role of exogenous IL-2. J Immunol (2005) 175(3):1593–8. doi:10.4049/jimmunol.175.3.1593

60. Simoni D, Gębba N, Invidiata FP, Eleopra M, Marchetti P, Rondonin R, et al. Design, synthesis, and biological evaluation of novel aminobisphosphonates possessing an in vivo antitumor activity through a gammadelta-T lymphocytes-mediated activation mechanism. J Med Chem (2008) 51(2):6800–78. doi:10.1021/jm80030y

61. Beck BH, Kim HG, Kim H, Samuel S, Liu Z, Shrestha R, et al. Adoptively transferred ex vivo expanded gammadelta-T cells mediate in vivo antitumor activity in preclinical mouse models of breast cancer. Breast Cancer Res Treat (2012) 121(1):135–44. doi:10.1007/s10549-009-0527-6

62. D'Asaro M, La Mendola C, Di Liberto D, Orlando V, Todaro M, Spina M, et al. V gamma 9V delta 2 T lymphocytes efficiently recognize and kill zolendronic acid-sensitized, imatinib-sensitive, and imatinib-resistant chronic myelogenous leukemia cells. J Immunol (2010) 184(6):3268–9. doi:10.4049/jimmunol.0903545

63. Cappeito AH, Martinet L, Fouronne J. Stimulated gammadelta T cells increase the in vivo efficacy of trastuzumab in HER-2+ breast cancer. J Immunol (2011) 187(2):1031–8. doi:10.4049/jimmunol.1100081

64. Siegers GM, Felizardo TC, Mathieson AM, Kosaka Y, Wang X-H, Medin JA, et al. Anti-leukemia activity of in vitro-expanded human gamma delta T cells in a xenogeneic Ph(+) leukemia model. PLoS One (2011) 6(2):e16700. doi:10.1371/journal.pone.0016700

65. Santolaria T, Robard M, Léger A, Catros V, Bonneville M, Scotet E. Repeated systemic administrations of both aminobisphosphonates and human Vγ9Vδ2 T cells efficiently control tumor development in vivo. J Immunol (2013) 191(4):1993–2000. doi:10.4049/jimmunol.1300255

66. Sun L, Li Y, Jiang Z, Zhang J, Li H, Li B, et al. Vgamma9Vdelta2 T cells and zolendronate mediate antitumor activity in an orthotopic mouse model of human chondrosarcoma. Tumour Biol (2016) 37(6):7333–44. doi:10.1007/s13277-015-4615-4

67. Nada MH, Wang H, Workaleahu G, Tanaka Y, Morita CT. Enhancing Nada MH, Wang H, Workaleahu G, Tanaka Y, Morita CT. Enhancing T lymphocyte agonist in patients with solid tumors. Cancer Immun Immunother (2010) 59(10):1521–30. doi:10.1007/s00262-010-0879-0

68. Lang JM, Kauliabad MR, Wallace M, Staab MJ, Horvath DL, Widing G, et al. Pilot trial of interleukin-2 and zolendronic acid to augment gammadelta T cells as treatment for patients with refractory renal cell carcinoma. Cancer Immun Immunother (2011) 60(10):1447–60. doi:10.1007/s00262-010-0948-8

69. Bennouna J, Bompas E, Neidhardt EM, Rolland F, Philip I, Galea C, et al. Phase-I study of Innacell gammadelta, an autologous cell-therapy product highly enriched in gamma9delta2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma. Cancer Immun Immunother (2008) 57(11):1599–609. doi:10.1007/s00262-008-0491-8

70. Sakamoto M, Nakajima J, Murakawa T, Fukumi T, Yoshida Y, Murayama T, et al. Adoptive immunotherapy for advanced non-small cell lung cancer using zolendronate-expanded gammadeltaT-cells: a phase I clinical study. J Immunol (2011) 34(2):202–11. doi:10.1074/jimmunol.1100858

71. Noguchi A, Kaneko T, Kamigaki T, Fujimoto K, Ozawa M, Saito M, et al. Zolendronate-activated Vgamma9gammadelta T cell-based immunotherapy is feasible and restores the impairment of gammadelta T cells in patients with solid tumors. Cytotherapy (2011) 13(1):92–7. doi:10.1016/j.jcyt.2010.04.008

72. Kobayashi H, Tanaka Y, Yagi J, Osaka Y, Nakazawa H, Uchiyama T, et al. Safety profile and anti-tumor effects of adoptive immunotherapy using gamma-delta T cells against advanced renal cell carcinoma: a pilot study. Cancer Immun Immunother (2007) 56(4):469–76. doi:10.1007/s00262-006-0199-6

73. Kobayashi H, Tanaka Y, Yagi J, Minato N, Tanabe K. Phase I/II study of adoptive transfer of gammadelta T cells in combination with zolendronic acid and IL-2 to patients with advanced renal cell carcinoma. Cancer Immun Immunother (2011) 60(8):1075–84. doi:10.1007/s00262-011-1021-7

74. Abe Y, Muto M, Nieda M, Nakagawa T, Nicolaol A, Kaneko T, et al. Clinical and immunomolecular evaluation of zolendronate-activated Vgamma9gammadelta T cell-based immunotherapy for patients with multiple myeloma. Exp Hematol (2009) 37(8):956–68. doi:10.1016/j.exphem.2009.04.008

75. Nakajima J, Murakawa T, Fukumi T, Goto S, Kaneko T, Yoshida Y, et al. A phase I study of adoptive immunotherapy for recurrent non-small-cell lung cancer patients with autologous gammadelta T cells. Eur J Cardiothorac Surg (2010) 37(5):1191–7. doi:10.1016/j.ejcts.2009.11.051

76. Wilhelm M, Smetak M, Schaefer-Eckart K, Kimmel B, Birkmann J, Einsele H, et al. Successful adoptive transfer and in vivo expansion of haploidentical gammadelta T cells. J Transl Med (2014) 12:45. doi:10.1186/1479-5867-12-45

77. Tani T, Kondo M, Takahashi T, Fujiyama N, Kondo A, Tamura N, et al. Ex vivo characterization of gammadelta T-cell repertoire in patients after adoptive transfer of Vgamma9Vdelta2 T cells expressing the interleukin-2 receptor beta-chain and the common gamma-chain. Cytotherapy (2013) 15(4):481–91. doi:10.1016/j.jcyt.2012.12.004

78. Nicol AJ, Tokuyama H, Matarollo SR, Hagri T, Suzuki K, Yokokawa K, et al. Clinical evaluation of autologous gamma delta T cell-based immunotherapy for metastatic solid tumours. Br J Cancer (2011) 105(6):778–86. doi:10.1038/bjc.2011.293

79. Wada I, Matsushita H, Noji S, Yamashita H, Nomura S, et al. Intraperitoneal injection of in vitro expanded Vgamma9Vdelta2 T cells together with zolendronic for the treatment of malignant ascites due to gastric cancer. Cancer Med (2014) 3(2):362–75. doi:10.1002/cam4.196

80. Cui J, Wang N, Zhao H, Jin H, Wang G, Niu C, et al. Combination of radiofrequency ablation and sequential cellular immunotherapy improves progression-free survival for patients with hepatocellular carcinoma. Int J Cancer (2014) 132(2):342–51. doi:10.1002/ijc.23872

81. Lo Presti E, Pizzolato G, Giulotta E, Cordorillo G, Giulotta G, Dieli F, et al. Current advances in gammadelta T-cell-based tumor immunotherapy. Front Immunol (2017) 8:1401. doi:10.3389/fimmu.2017.01401

82. Kobayashi H, Tanaka Y. Gamma delta T cells as treatment for patients with refractory renal cell carcinoma. Cancer Immun Immunother (2011) 60(10):1447–60. doi:10.1007/s00262-011-0948-8
108. Morita CT, Jin C, Sarikonda G, Wang H. Nonpeptide antigens, presentation

103. Altincicek B, Moll J, Campos N, Foerster G, Beck E, Hoeffler J-F, et al. Cutting

102. Renner K, Singer K, Koehl GE, Geissler EK, Peter K, Siska PJ, et al. Meta-

105. Gober HJ, Kistowska M, Angman L, Jeno P, Mori L, De Libero G. Human T-cell

100. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation.

99. Gruenbacher G, Nussbaumer O, Gander H, Steiner B, Leonhartsberger N,

94. Brandes M, Willimann K, Lang AB, Nam K-H, Jin C, Brenner MB, et al. Flexible migration program regulates γδ T-cell involvement in humoral immunity. Blood (2003) 102(10):3693–701. doi:10.1182/blood-2003-04-1016

Khan MW, Ebel M, Moser B. Potential use of [gammadelta] T-cell based vac-

Paul S, Lal G. Regulatory and effector functions of gamma–delta (γδ) T cells and their therapeutic potential in adoptive cellular therapy for cancer. J Exp Med (2010) 204(11):2537–44. doi:10.1084/jem.2010.1778

Marcu-Malina V, Heijhuurs S, van Buuren M, Hartkamp L, Strand S, Sebestyen Z, et al. Redirecting alpha beta T cells against cancer cells by transfer of a broadly tumor-reactive γδ T-cell receptor. Blood (2011) 118(1):30–9. doi:10.1182/blood-2010-12-325993

Ribeiro ST, Ribot JC, Silva-Santos B. Five layers of receptor signaling in gammadelta T-cell differentiation and activation. Front Immunol (2015) 5:615. doi:10.3389/fimmu.2015.00615

Gruenbacher G, Nussbaumer O, Gander H, Steiner B, Leonhartsberger N, Thurnher M. Stress-related and homeostatic cytokines regulate Vγ9Vδ2 T-cell surveillance of mevalonate metabolism. Oncoimmunology (2014) 3(8):e953410. doi:10.4161/21644211.2014.953410

Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell (2011) 144(5):646–74. doi:10.1016/j.cell.2011.02.013

Warburg O, Posener K, Negelein E. Über den Stoffwechsel der Carcinomzelle. Biochem Z (1924) 152:309–44.

Renner K, Singer K, Koehl GE, Geissler EK, Peter K, Siska PJ, et al. Metabo-

Altincicek B, Moll J, Campos N, Foerster G, Beck E, Hoefferl J-F, et al. Cutting edge: human gamma delta T cells are activated by intermediates of the 2-C-methyl-D-erythritol 4-phosphate pathway of isoprenoid biosynthesis. J Immunol (2001) 166(5):3655–8. doi:10.4049/jimmunol.166.6.3655

Coscia M, Vitale C, Peola S, Foglietta M, Rigoni M, Griggio V, et al. Dysfunctional Vγ9Vδ2 T cells are negative prognosticators and markers of dysregulated mevalonate pathway activity in chronic lympho-

Gober HJ, Kistowska M, Angman L, Jeno P, Mori L, De Libero G. Human T cell receptor gammadelta2 cells recognize endogenous mevalonate metabolites in tumor cells. J Exp Med (2003) 197(2):163–9. doi:10.1084/jem.20021300

Gruenbacher G, Thurnher M. Mevalonate metabolism governs cancer immune surveillance. Oncoimmunology (2017) 6(10):e1342917. doi:10.18632/oncoimmunology.2017.6.1342917

Harwood HJ Jr, Alvarez IM, Noyes WD, Stacpoole PW. In vivo regulation of human leukocyte 3-hydroxy-3-methylglutaryl coenzyme A reductase: increased enzyme protein concentration and catalytic efficiency in human leukemia and lymphoma. J Lipid Res (1991) 32(8):1237–52.

Morita CT, Jin C, Sarikonda G, Wang H. Nonpeptide antigens, presentation

Moar J, Matsushita H, Hoshikawa M, Hasegawa K, Kokudo N, Kakimi K. Aoki T, Matsushita H, Hoshikawa M, Hasegawa K, Kakimi K. Adjuvant combination therapy with gemcitabine and autologous gammadelta T-cell transfer in patients with curatively resected pancreatic cancer. Cytotherapy (2013) 15(7):2583–40. doi:10.1016/j.jcyt.2013.09.002
129. Miyagawa F, Tanaka Y, Yamashita S, Minato N. Essential requirement of the absence of an allogeneic response. *Bone Marrow Transplant* (2001) 27(6):601–6. doi:10.1038/sj.bmt.1702830

130. Roelofs AJ, Jauhiainen M, Monkkonen H, Rogers MJ, Monkkonen J, Thompson K. Peripheral blood monocytes are responsible for gammadelta T cell activation induced by zoledronic acid through accumulation of IPP/DMAPP. *Br J Haematol* (2009) 144(2):245–50. doi:10.1111/j.1365-2141.2008.07435.x

131. Workalemahu G, Wang H, Puan KJ, Nada MH, Kuzuyama T, Jones BD, et al. Resistance of cyclooxygenase-2 expressing pancreatic ductal adenocarcinoma cells against γδ T lymphocytes. *Blood* (2012) 120(11):4085–93. doi:10.1182/blood-2012-04-450470

132. Kennel KA, Drake MT. Adverse effects of bisphosphonates: implications for anticancer immunotherapy. *Nat Commun* (2017) 8:15663. doi:10.1038/ncomms15663

133. Tanaka Y, Iwasaki M, Murata-Hirai K, Matsumoto K, Hayashi K, Okamura H, et al. Anti-tumor activity and immunotherapeutic potential of a phosphoantigen prodrug that potently activates Vγ9Vδ2 T cells. *Oncoimmunology* (2014) 3:84(7):632–8. doi:10.1080/2162402X.2014.988460

134. Matsug-Reuther S, Deucluc T, Besombes C, Poupot M, Savina A, Olive D, et al. Targeting cancer cells with a bisphosphonate prodrug. *ChemMedChem* (2016) 11(24):2656–63. doi:10.1002/cmdc.201600465

135. Hodgins NO, Wang JT, Al-Jamal KT. Nano-technology based carriers for nitrogen-containing bisphosphonates delivery as sensitisers of gammadelta T cells. *Adv Drug Deliv Rev* (2016) 116:55–54. doi:10.1016/j.addr.2016.08.006

136. Kennel KA, Drake MT. Adverse effects of bisphosphonates: implications for anticancer immunotherapy. *Nat Commun* (2017) 8:15663. doi:10.1038/ncomms15663

137. Kankotia S, Stacpoole PW. Dichloroacetate and cancer: new home for an orphan drug? *Paracelsus Science Get Together 2015; 03.07.2015; Nuremberg* 66 p.

138. Calcif Tissue Int (2014) 144(2):1365-1418. doi:10.1111/j.1365-2141.2008.07435.x

139. Hsiao CH, Lin X, Barney RJ, Shippy RR, Li J, Vinogradova O, et al. Synthesis of a phosophoantigen prodrug that potently activates Vγ9Vδ2 T cell immunity. *J Immunol* (2014) 193(2):708–21. doi:10.4049/jimmunol.1302746

140. Jarry U, Chauvin C, Joalland N, Leger A, Minault S, Robard M, et al. Phosphoantigen-induced conformational change of butyrophilin 3A1 (BTN3A1) and its implication on Vγ9Vδ2 T cell receptor. *Cell Rep* (2016) 15(9):1973–85. doi:10.1016/j.celrep.2016.04.081

141. Hodgins NO, Wang JT, Al-Jamal KT. Nano-technology based carriers for nitrogen-containing bisphosphonates delivery as sensitisers of gammadelta T cells. *Adv Drug Deliv Rev* (2016) 116:55–54. doi:10.1016/j.addr.2016.08.006

142. Butyrophilin 3A (BTN3A, CD277)-specific antibody 20.1 differentially activates Vγ9Vδ2 T-Cell Immunotherapy in Cancer. *Frontiers in Immunology* (2013) 14(9):908–16. doi:10.3389/fimmu.2013.01583

143. Kankotia S, Stacpoole PW. Dichloroacetate and cancer: new home for an orphan drug? *Paracelsus Science Get Together 2015; 03.07.2015; Nuremberg* 66 p.

144. Kankotia S, Stacpoole PW. Dichloroacetate and cancer: new home for an orphan drug? *Paracelsus Science Get Together 2015; 03.07.2015; Nuremberg* 66 p.

145. Cragg MG, Smith RD. Anti-tumor activity and immunotherapeutic potential of a phosphoantigen prodrug. *ChemMedChem* (2016) 11(24):2656–63. doi:10.1002/cmdc.201600465

146. Compte E, Pontarotti P, Collette Y, Lopez M, Olive D. Frontline: characterisation of BT3 membrane proteins belonging to the B7 family expressed on immune cells. *Eur J Immunol* (2004) 34(4):809–99. doi:10.1002/eji.200425227

147. Nguyen K, Li J, Puthenveetil R, Lin X, Poe MM, Hisao CC, et al. The butyrophilin 3A1 intracellular domain undergoes a conformational change involving the juxtamembrane region. *FASEB J* (2017) 31(11):4697–706. doi:10.1096/fj.20161370RR

148. Gundacker B, Gander H, Rahm A, Idzko M, Nussbaumer O, Thurnher M. Ecto-ATPase CD39 inactivates isorenoid-derived Vγ9Vδ2 T cells.
T cell phosphorytogens. Cell Rep (2016) 16(2):444–56. doi:10.1016/j.celrep.2016.06.009

Egle A, Ahuja SP, Matloub Y. L-asparaginase in the treatment of patients with acute lymphoblastic leukemia. J Pharmcol Pharmacother (2016) 7(2):62–71. doi:10.4103/0976-500X.184769

Chang CH, Pearce EL. Emerging concepts of T cell metabolism as a target of immunotherapy. Nat Immunol (2016) 17(4):364–8. doi:10.1038/nli.3415

Bauer S, Groh V, Wu J, Steinle A, Phillips JH, Lanier LL, et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science (1999) 285(5428):727–9. doi:10.1126/science.285.5428.727

Diefenbach A, Jamieson AM, Liu SD, Shastri N, Raulet DH. Ligands for the murine NKG2D receptor: expression by tumor cells and activation of NK cells and macrophages. Nat Immunol (2000) 1(2):119–26. doi:10.1038/sj.ni.5000779

Groh V, Rhinehart R, Randolph-Habecker J, Topp MS, Riddell SR, Spies T. Costimulation of CD8αβ T cells by NKG2D via engagement by MIC induced on infected cells. Nat Immunol (2001) 2(3):255–60. doi:10.1038/85321

Garry D, Call ME, Feng J, Wucherpfennig KW. The activating NKG2D receptor assemblies in the membrane with two signaling dimers into a hexameric structure. Proc Natl Acad Sci U S A (2005) 102(21):7641–6. doi:10.1073/pnas.0502439102

Eagle RA, Trowsdale J. Promiscuity and the single receptor: NKG2D. Immunol Rev (2005) 204(1):231–7. doi:10.1111/j.0903-1936.2005.00306.x

Obeidy P, Sharland AF. NKG2D and its ligands. Immunol J (2005) 39(6):145–52. doi:10.3892/ijo.2011.1144

Guenther R. Influence of Several Immunomodulatory Drugs and Receptor-Ligand-Systems on the γδ T Cell Effector Function against Leukemia. Nuremberg: Paracelsus Medical University (2015).

Niu C, Jin H, Li M, Zhu S, Zhou L, Jin F, et al. Low-dose bortezomib increases the expression of NKG2D and DNAM-1 ligands and enhances induced NK and gammagamma delta T cell-mediated lysis in multiple myeloma. Oncotarget (2017) 8(4):3954–64. doi:10.18632/oncotarget.13979

Bhat J, Kabelitz D. Gammadelta T cells and epigenetic drugs: a useful merger in cancer immunotherapy? Oncotarget (2015) 4(6):e100688. doi:10.18632/oncotarget.100688

Suzuki T, Terao S, Acharaya B, Naoe M, Yamamoto S, Okamura H, et al. The antitumour effect of [gamma][delta] T cells is enhanced by valproic acid-induced up-regulation of NKG2D ligands. Anticancer Res (2010) 30(11):4509–13.

Chavez-Blanco A, De la Cruz-Hernandez E, Dominguez GI, Rodriguez-Cortez O, Alatorre B, Perez-Cardenas E, et al. Upregulation of NKG2D ligands and enhanced natural killer cell cytotoxicity by hydralazine and valproate. Int J Oncol (2011) 39(6):1491–9. doi:10.3892/ijo.2011.1144

Sattanathan B, Vavishi S, Saha A, Zhao F, Ayello J, van de Ven C, et al. Upregulation of NKG2D ligands in acute lymphoblastic leukemia and non-Hodgkin lymphoma cells by romidepsin and enhanced in vitro and in vivo natural killer cell cytotoxicity. Cytotherapy (2014) 16(10):1431–40. doi:10.1016/j.jcyt.2014.03.008

Alsaab HO, Sau S, Alzhari R, Tattiparti K, Bhise K, Kashaw SK, et al. PD-1 and PD-1-L checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome. Front Immunol (2017) 8:561. doi:10.3389/fimmu.2017.00561

Boussiotis VA. Molecular and biochemical aspects of the PD-1 checkpoint pathway. Nat Rev Drug Discov (2005) 4(18):1767–78. doi:10.1038/nrd164926

Pedoeaa A, Azoulay-Alfaguer I, Strazza M, Silverman GJ, Mor A. Programmed death-1 pathway in cancer and autoimmunity. Clin Immunol (2014) 153(1):145–52. doi:10.1016/j.clim.2014.04.010

Carey CD, Guseleiten D, Lipschitz M, Roemer MGM, Stack EC, Gini E, et al. Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma. Blood (2017) 130(22):2420–30. doi:10.1182/blood-2017-03-770719

Iwasaki M, Tanaka Y, Kobayashi H, Murata-Hirai K, Miyabe H, Sugie T, et al. Expression and function of PD-1 in human gammagamma delta T cells that recognize phosphorytogens. Eur J Immunol (2011) 41(2):345–55. doi:10.1002/eji.201040959

Paquin-Proulx D, Barsotti NS, Santos BA, Marinho AK, Kokron CM, Carvalho KL, et al. Inversion of the Vdelta1 to Vdelta2 gammagamma delta T cell ratio in CVID is not restored by IVIg and is associated with immune activation and exhaustion. Medicine (Baltimore) (2016) 95(30):e4304. doi:10.1097/MD.0000000000004304

Zumwaltke NA, Sharma A, Xu X, Ma S, Schneider CL, Romero-Masters JC, et al. Adoptively transferred Vgamma9Vdelta2 T cells show potent antitumor effects in a preclinical B cell lymphomasmesis model. JCI Insight (2017) 2(13):93179. doi:10.1172/jci.insight.93179

Hau H, Bououda S, Myula G, Dyawl HC, Mungwira RG, Harman C, et al. Prolonged PD1 expression on neonatal Vdelta2 lymphocytes dampens proinflammatory responses: role of episomatic regulation. J Immunol (2016) 197(5):1884–92. doi:10.4049/jimmunol.1600284

Castella B, Foglietta M, Sciancalepore P, Rigoni M, Coscia M, Griggio V, et al. Adoptively transferred Vdelta2 T cells show potent antitumor effects in a preclinical B cell lymphomasmesis model. JCI Insight (2017) 2(13):93179. doi:10.1172/jci.insight.93179

Sakouki K, Apetoh L, Sullivan JM, Blazar BR, Kuchroo VK, Anderson AC. Targeting TIM-3 and PD-1 pathways to reverse T cell exhaustion and restore

Frontiers in Immunology | www.frontiersin.org 16 April 2018 | Volume 9 | Article 800
211. Seidel UJ, Vogt F, Grosse-Hovest L, Jung G, Handgretinger R, Lang P.
210. Peters C, Oberg HH, Kabelitz D, Wesch D. Phenotype and regulation of
209. Jagannathan P, Lutwama F, Boyle MJ, Nankya F, Farrington LA, McIntyre TI,
207. Parry RV, Chemnitz JM, Frauwirth KA, Lanfranco AR, Braunstein I,
206. Yang Z-Z, Kim HJ, Villasboas JC, Chen Y-P, Price-Troska T, Jalali S, et al.
205. Gertner-Dardenne J, Fauriat C, Orlanducci F, Thibult ML, Pastor S,
203. Koyama S, Akbay EA, Li YY, Herter-Sprie GS, Buczkowski KA, Richards WG,
204. Watanabe N, Gavrieli M, Sedy JR, Yang J, Fallarino F, Loftin SK, et al.
215. Braza MS, Klein B, Fiol G, Rossi JF. Gammadelta T-cell killing of primary
217. Mossner E, Brunker P, Moser S, Puntener U, Schmidt C, Herter S, et al.
216. Niu C, Jin H, Li M, Xu J, Xu D, Hu J, et al. In vitro analysis of the proliferative
219. Schiller CB, Braciak TA, Fenn NC, Seidel UJE, Roskopf CC, Wildenhain S,
Front Immunol
217. Mossner E, Brunker P, Moser S, Puntener U, Schmidt C, Herter S, et al.
216. Niu C, Jin H, Li M, Xu J, Xu D, Hu J, et al. In vitro analysis of the proliferative
219. Schiller CB, Braciak TA, Fenn NC, Seidel UJE, Roskopf CC, Wildenhain S,
217. Mossner E, Brunker P, Moser S, Puntener U, Schmidt C, Herter S, et al.
216. Niu C, Jin H, Li M, Xu J, Xu D, Hu J, et al. In vitro analysis of the proliferative
219. Schiller CB, Braciak TA, Fenn NC, Seidel UJE, Roskopf CC, Wildenhain S,
217. Mossner E, Brunker P, Moser S, Puntener U, Schmidt C, Herter S, et al.
216. Niu C, Jin H, Li M, Xu J, Xu D, Hu J, et al. In vitro analysis of the proliferative
219. Schiller CB, Braciak TA, Fenn NC, Seidel UJE, Roskopf CC, Wildenhain S,
217. Mossner E, Brunker P, Moser S, Puntener U, Schmidt C, Herter S, et al.
216. Niu C, Jin H, Li M, Xu J, Xu D, Hu J, et al. In vitro analysis of the proliferative
219. Schiller CB, Braciak TA, Fenn NC, Seidel UJE, Roskopf CC, Wildenhain S,
217. Mossner E, Brunker P, Moser S, Puntener U, Schmidt C, Herter S, et al.
216. Niu C, Jin H, Li M, Xu J, Xu D, Hu J, et al. In vitro analysis of the proliferative
219. Schiller CB, Braciak TA, Fenn NC, Seidel UJE, Roskopf CC, Wildenhain S,
217. Mossner E, Brunker P, Moser S, Puntener U, Schmidt C, Herter S, et al.
216. Niu C, Jin H, Li M, Xu J, Xu D, Hu J, et al. In vitro analysis of the proliferative
219. Schiller CB, Braciak TA, Fenn NC, Seidel UJE, Roskopf CC, Wildenhain S,
217. Mossner E, Brunker P, Moser S, Puntener U, Schmidt C, Herter S, et al.
216. Niu C, Jin H, Li M, Xu J, Xu D, Hu J, et al. In vitro analysis of the proliferative
219. Schiller CB, Braciak TA, Fenn NC, Seidel UJE, Roskopf CC, Wildenhain S,
217. Mossner E, Brunker P, Moser S, Puntener U, Schmidt C, Herter S, et al.
216. Niu C, Jin H, Li M, Xu J, Xu D, Hu J, et al. In vitro analysis of the proliferative
219. Schiller CB, Braciak TA, Fenn NC, Seidel UJE, Roskopf CC, Wildenhain S,
217. Mossner E, Brunker P, Moser S, Puntener U, Schmidt C, Herter S, et al.
216. Niu C, Jin H, Li M, Xu J, Xu D, Hu J, et al. In vitro analysis of the proliferative
219. Schiller CB, Braciak TA, Fenn NC, Seidel UJE, Roskopf CC, Wildenhain S,
217. Mossner E, Brunker P, Moser S, Puntener U, Schmidt C, Herter S, et al.
216. Niu C, Jin H, Li M, Xu J, Xu D, Hu J, et al. In vitro analysis of the proliferative
219. Schiller CB, Braciak TA, Fenn NC, Seidel UJE, Roskopf CC, Wildenhain S,
217. Mossner E, Brunker P, Moser S, Puntener U, Schmidt C, Herter S, et al.
216. Niu C, Jin H, Li M, Xu J, Xu D, Hu J, et al. In vitro analysis of the proliferative
219. Schiller CB, Braciak TA, Fenn NC, Seidel UJE, Roskopf CC, Wildenhain S,
217. Mossner E, Brunker P, Moser S, Puntener U, Schmidt C, Herter S, et al.
216. Niu C, Jin H, Li M, Xu J, Xu D, Hu J, et al. In vitro analysis of the proliferative
219. Schiller CB, Braciak TA, Fenn NC, Seidel UJE, Roskopf CC, Wildenhain S,
soluble VEGF receptor-1. Clin Exp Immunol (2017) 192(1):54–67. doi: 10.1111/cei.13090

238. Glatzel A, Wesch D, Schiemann F, Brandt E, Janssen O, Kabelitz D. Patterns of chemokine receptor expression on peripheral blood gamma delta T lymphocytes: strong expression of CCR5 is a selective feature of V delta 2/V gamma 9 gamma delta T cells. J Immunol (2002) 168(10):4920–9. doi: 10.4049/jimmunol.168.10.4920

239. Viey E, Lucas C, Romagne F, Escudier B, Chouaib S, Caignard A. Chemokine receptors expression and migration potential of tumor-infiltrating and peripheral-expanded V gamma 9 V delta 2 T cells from renal cell carcinoma patients. J Immunother (2008) 31(3):313–23. doi: 10.1097/CJI.0b013e3181609988

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2018 Hoeres, Smetak, Pretscher and Wilhelm. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.